Do Billionaires Chase Coleman and David Tepper Know Something About UnitedHealth Stock That Wall Street Doesn't?

UnitedHealth reported Q1 2026 results that beat revenue and earnings estimates, with the medical cost ratio improving 90 bps to 83.9%, suggesting costs are coming under control. Despite billionaire selling by Chase Coleman and David Tepper in Q1, 22 of 28 analysts surveyed by S&P Global still rate the stock a buy or strong buy. The article frames the setup as mixed in the short term but supportive of the company’s long-term outlook.

Analysis

The sell-down by high-profile hedge funds looks more like a relative-value rotation than a clean bearish call on the insurer. In a market where semis and AI-linked growth are absorbing incremental risk capital, a large-cap defensive compounder can get de-rated even if fundamentals are stabilizing; that creates a classic “good business, poorer opportunity set” dynamic. The second-order implication is that capital is being pulled toward higher-beta winners, which can keep UNH underowned even as earnings quality improves.

What matters now is not sentiment but whether medical cost trends remain contained for 2-3 more quarters. If the cost ratio keeps trending lower, the market will likely re-rate UNH quickly because the stock has enough scale and index ownership to attract mean-reversion buyers once uncertainty fades. But if Medicare Advantage pricing or utilization re-accelerates, the multiple can compress again fast; this is a months-not-days story, with regulatory headlines and next quarter’s cost data the key catalysts.

The contrarian read is that the billionaire exits may actually be a useful signal for short-term sentiment, but not for medium-term fundamentals. The better trade is to separate timing from thesis: the stock can be structurally attractive for long-only investors while still offering tactical downside if the market is over-anticipating margin recovery. Berkshire’s exit also matters less than it appears because portfolio construction changes at large holders can create mechanical selling unrelated to valuation, which often leaves a short-lived dislocation rather than a permanent break in the story.

Key Decisions for Investors

• Enter a tactical long UNH on 1-2 week weakness after any headline-driven selloff; target a 3-5% rebound if next cost data remains benign, with a tighter stop if managed-care peers weaken simultaneously.
• Pair trade: long UNH / short a high-multiple AI/semiconductor basket over 1-3 months to express defensive re-rating versus growth crowding; the edge is mean reversion in capital flows, not absolute market direction.
• Buy UNH call spreads 2-4 months out to capture a potential post-earnings or regulatory relief pop while limiting drawdown if Medicare Advantage headlines deteriorate.
• Avoid adding aggressively until the next read-through on medical loss trends; if the cost ratio stops improving for two consecutive quarters, the bull case becomes a value trap and the position should be cut.